Lyell Immunopharma reported revenue of $0.00M and net income of -$45.65M for the quarter ended Sep 2026, down 80.0% year over year. This income statement covers 26 quarters of results from Jun 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | 2.82M | 0.55M | 35.74M | 0.00M | 48.39M | 0.07M | 0.03M | 0.03M | 0.01M | 0.00M | 0.01M | 0.03M | 0.01M | 0.01M | 0.01M | 0.02M | 0.01M | 0.00M | 0.00M | 0.00M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 19.29M | 35.83M | 43.72M | 41.61M | 38.03M | 44.63M | 47.47M | 43.85M | 47.00M | 43.17M | 40.26M | 39.50M | 48.67M | 43.45M | 34.86M | 28.17M | 52.20M | 36.60M | 39.52M | 40.90M | ||||||
| Selling, General & AdministrativeSG&A | 31.87M | 34.42M | 30.45M | 26.08M | 26.35M | 19.28M | 19.03M | 15.51M | 13.17M | 13.49M | 12.26M | 11.77M | 14.52M | 14.05M | 9.79M | 10.69M | 10.62M | 9.56M | 9.58M | 9.30M | ||||||
| Other Operating ExpensesOther Opex | 0.80M | 1.12M | 1.17M | 1.25M | 1.21M | 1.29M | 0.57M | 0.29M | 0.64M | 1.09M | 0.98M | 0.73M | 0.51M | 0.12M | -1.06M | 1.59M | 1.50M | 1.90M | 1.76M | 1.90M | ||||||
| Operating ExpensesOpex | 50.36M | 69.13M | 73.00M | 66.44M | 63.17M | 62.62M | 65.93M | 59.06M | 59.52M | 55.58M | 51.54M | 50.54M | 201.16M | 57.37M | 47.15M | 37.27M | 127.65M | 44.26M | 47.34M | 48.30M | ||||||
| Operating IncomeOp. Inc | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | -48.30M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Goodwill impairment chargesGoodwill Impair. | 51.30M | 1.44M | ||||||||||||||||||||||||
| Gains (Losses) on Sale of Assets & InvestmentsGains on Sales | -1.56M | -4.98M | -1.75M | -1.65M | 2.40M | 3.72M | 1.50M | 1.20M | 1.09M | -0.31M | 0.01M | 1.16M | -0.47M | -0.13M | -0.10M | 0.14M | 0.04M | -0.25M | -0.15M | -0.12M | ||||||
| Interest & Investment IncomeInt & Inv Inc | ||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.04M | 0.04M | -0.01M | -1.07M | 2.93M | 1.10M | -0.33M | 1.58M | -0.51M | 1.09M | -0.65M | -0.04M | 4.29M | 1.31M | 1.18M | -4.86M | -15.76M | 17.91M | 0.40M | 0.86M | ||||||
| Non Operating IncomeNon Op. Inc. | -36.17M | 0.43M | 0.94M | -3.82M | 6.39M | -4.40M | 2.02M | 8.19M | 6.58M | -5.09M | 5.72M | 5.92M | 9.21M | 5.17M | 4.46M | -1.59M | -13.08M | 20.11M | 2.58M | 2.77M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBIT | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | -48.30M | ||||||
| EBT | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | -48.30M | ||||||
| Income After Tax | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | -48.30M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -47.54M | -68.58M | -37.26M | -66.44M | -14.78M | -62.56M | -65.91M | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M | -201.15M | -57.37M | -47.14M | -37.25M | -127.64M | -44.26M | -47.34M | -48.30M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -85.26M | -73.12M | -38.07M | -71.90M | -6.00M | -63.24M | -62.39M | -49.66M | -51.84M | -60.98M | -45.80M | -43.43M | -192.40M | -52.33M | -42.79M | -38.70M | -140.68M | -24.40M | -44.90M | -45.65M | ||||||
| Income towards Parent CompanyParent Net Inc | -83.71M | -68.14M | -36.32M | -70.25M | -8.40M | -66.96M | -63.89M | -50.85M | -52.93M | -60.67M | -45.81M | -44.58M | -191.94M | -52.20M | -42.68M | -38.85M | -140.72M | -24.15M | -44.76M | -45.53M | ||||||
| Preferred Dividend PaymentsPref Dividends | -3.58M | |||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -83.71M | -68.14M | -36.32M | -70.25M | -8.40M | -66.96M | -63.89M | -50.85M | -52.93M | -60.67M | -45.81M | -44.58M | -191.94M | -52.20M | -42.68M | -38.85M | -140.72M | -24.15M | -44.76M | -45.53M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -12.32 | -5.58 | -2.95 | -5.66 | -0.68 | -5.37 | -5.11 | -4.05 | -4.22 | -4.77 | -3.59 | -3.48 | -14.68 | -3.54 | -2.89 | -2.13 | -8.23 | -1.10 | -1.92 | -1.86 | ||||||
| EPS (Diluted) | -12.32 | -5.58 | -2.95 | -5.66 | -0.68 | -5.37 | -5.11 | -4.05 | -4.22 | -4.77 | -3.59 | -3.48 | -14.68 | -3.54 | -2.89 | -2.13 | -8.23 | -1.10 | -1.92 | -1.86 | ||||||
| Shares Outstanding | 6.80M | 12.21M | 12.32M | 12.42M | 12.35M | 12.48M | 12.51M | 12.57M | 12.55M | 12.71M | 12.77M | 12.82M | 13.07M | 14.75M | 14.79M | 18.27M | 17.09M | 21.88M | 23.36M | 24.44M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 6.80M | 12.21M | 12.32M | 12.42M | 12.35M | 12.48M | 12.51M | 12.57M | 12.55M | 12.71M | 12.77M | 12.82M | 13.07M | 14.75M | 14.79M | 18.27M | 17.09M | 21.88M | 23.36M | 24.44M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 6.80M | 12.27M | 12.36M | 12.46M | 12.48M | 12.48M | 12.55M | 12.59M | 12.70M | 12.75M | 12.80M | 12.83M | 14.74M | 14.76M | 14.83M | 18.27M | 17.09M | 23.33M | 23.40M | 24.58M | ||||||
| EBITDA | -42.97M | -64.39M | -33.09M | -61.82M | -9.74M | -57.53M | -60.84M | -53.94M | -54.45M | -50.55M | -46.63M | -45.83M | -196.12M | -53.93M | -44.01M | -34.69M | -125.25M | -41.93M | -45.12M | -46.24M |
Pull Lyell Immunopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=LYEL&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "LYEL", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=LYEL&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();